BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
BioStem Technologies (OTC: BSEM) announces its participation in the 17th Annual LD Micro Main Event, scheduled for October 28-30, 2024, at the Luxe Sunset Boulevard Hotel in Los Angeles. Jason Matuszewski, Founder and CEO, will deliver a live presentation on October 30 at 9:30 AM PT and conduct one-on-one meetings.
The company has reported significant achievements in 2024, including record-breaking revenue of $116 million in the first six months. Recent milestones include breakthrough results in diabetic foot ulcer studies, establishing national pricing for Vendaje AC®, initiating the BR-AC-DFU-101 clinical trial, filing Form 10 with SEC, submitting a Nasdaq uplisting application, and receiving IRB approval for Vendaje® clinical study.
BioStem Technologies (OTC: BSEM) annuncia la sua partecipazione al 17° Annual LD Micro Main Event, in programma dal 28 al 30 ottobre 2024, presso il Luxe Sunset Boulevard Hotel di Los Angeles. Jason Matuszewski, Fondatore e CEO, terrà una presentazione dal vivo il 30 ottobre alle 9:30 AM PT e condurrà incontri one-to-one.
L'azienda ha riportato risultati significativi nel 2024, inclusi un fatturato record di 116 milioni di dollari nei primi sei mesi. I recenti traguardi includono risultati innovativi negli studi sulle ulcere del piede diabetico, l'istituzione di un prezzo nazionale per Vendaje AC®, l'avvio della sperimentazione clinica BR-AC-DFU-101, la presentazione del Modulo 10 alla SEC, l'invio di una domanda per il passaggio al Nasdaq e l'ottenimento dell'approvazione dell'IRB per lo studio clinico di Vendaje®.
BioStem Technologies (OTC: BSEM) anuncia su participación en el 17º Evento Principal Anual LD Micro, programado para el 28-30 de octubre de 2024, en el Luxe Sunset Boulevard Hotel en Los Ángeles. Jason Matuszewski, fundador y CEO, ofrecerá una presentación en vivo el 30 de octubre a las 9:30 AM PT y llevará a cabo reuniones individuales.
La empresa ha informado logros significativos en 2024, incluyendo ingresos récord de 116 millones de dólares en los primeros seis meses. Los hitos recientes incluyen resultados innovadores en estudios sobre úlceras en pies diabéticos, el establecimiento de precios nacionales para Vendaje AC®, el inicio del ensayo clínico BR-AC-DFU-101, la presentación del Formulario 10 a la SEC, la solicitud de uplisting en Nasdaq y la obtención de aprobación de IRB para el estudio clínico de Vendaje®.
BioStem Technologies (OTC: BSEM)는 2024년 10월 28일부터 30일까지 로스앤젤레스의 Luxe Sunset Boulevard Hotel에서 열리는 제17회 LD Micro 메인 이벤트에 참가할 것임을 발표했습니다. 제이슨 마투셰프스키 창립자 겸 CEO는 10월 30일 오전 9시 30분 PT에 라이브 발표를 하고 1:1 미팅을 진행할 예정입니다.
회사는 2024년 동안 1억 1,600만 달러의 기록적인 수익을 포함한 상당한 성과를 보고했습니다. 최근 이정표에는 당뇨병성 발 궤양 연구에서의 혁신적인 결과, Vendaje AC®의 국가 가격 책정 수립, BR-AC-DFU-101 임상 시험 시작, SEC에 Form 10 제출, Nasdaq 상장 신청서 제출 및 Vendaje® 임상 연구에 대한 IRB 승인 획득이 포함됩니다.
BioStem Technologies (OTC: BSEM) annonce sa participation au 17ème Événement Principal Annuel LD Micro, prévu du 28 au 30 octobre 2024, à l'hôtel Luxe Sunset Boulevard à Los Angeles. Jason Matuszewski, Fondateur et PDG, présentera en direct le 30 octobre à 9h30 PT et effectuera des réunions individuelles.
L'entreprise a rapporté des résultats significatifs en 2024, incluant un chiffre d'affaires record de 116 millions de dollars au cours des six premiers mois. Parmi les jalons récents, citons des résultats révolutionnaires dans les études sur les ulcères du pied diabétique, l'établissement d'un prix national pour Vendaje AC®, le lancement de l'essai clinique BR-AC-DFU-101, le dépôt du formulaire 10 auprès de la SEC, la soumission d'une demande d'inscription au Nasdaq et l'obtention de l'approbation de l'IRB pour l'étude clinique de Vendaje®.
BioStem Technologies (OTC: BSEM) gibt seine Teilnahme an der 17. jährlichen LD Micro Main Event bekannt, die vom 28. bis 30. Oktober 2024 im Luxe Sunset Boulevard Hotel in Los Angeles stattfinden wird. Jason Matuszewski, Gründer und CEO, wird am 30. Oktober um 9:30 Uhr PT eine Live-Präsentation halten und individuelle Meetings durchführen.
Das Unternehmen hat 2024 erhebliche Erfolge gemeldet, darunter Rekordeinnahmen von 116 Millionen US-Dollar in den ersten sechs Monaten. Zu den jüngsten Meilensteinen gehören bahnbrechende Ergebnisse in Studien zu diabetischen Fußgeschwüren, die Etablierung nationaler Preise für Vendaje AC®, der Beginn der klinischen Studie BR-AC-DFU-101, die Einreichung des Formulars 10 bei der SEC, die Einreichung eines Antrags auf Nasdaq-Uplisting und die Erteilung der IRB-Zulassung für die klinische Studie von Vendaje®.
- None.
- None.
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles
Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, is pleased to announce that Jason Matuszewski, Founder and CEO of BioStem, will participate in the 17th Annual LD Micro Main Event, taking place at the Luxe Sunset Boulevard Hotel in Los Angeles from October 28-30, 2024. Mr. Matuszewski will provide a live presentation on Wednesday, October 30, 2024, at 9:30 AM PT (12:30 PM ET) and will conduct in-person 1-on-1 meetings at the conference venue.
LD Micro Main Event XVII Presentation Information:
- Presenter: Jason Matuszewski, Founder and CEO
- Presentation Date: Wednesday, October 30th
- Presentation Time: 9:30AM PT - Track #1
- Webcast Registration: To watch the live virtual presentation, click HERE.
- 1x1 Meetings: Please contact your LD Micro representative or Jramson@pcgadvisory.com
Recent Corporate Events:
BioStem Technologies has experienced a transformative first half of 2024, reporting a record-breaking
October 2024:
- BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
- BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
- BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
September 2024:
- BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
August 2024:
- BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
- BioStem Technologies Reports Record Second Quarter 2024 Revenue of
$74.5 Million ;$116.4 million in revenue for the first half of 2024
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap 2 ™, VENDAJE ®, VENDAJE AC ®, and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
About LD Micro:
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com. To present or register, please contact registration@ldmicro.com.
Join BioStem's Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on Twitter and LinkedIn.
Forward-Looking Statements:
Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227509
FAQ
When will BioStem Technologies (BSEM) present at the LD Micro Main Event XVII?
What was BioStem Technologies (BSEM) revenue for the first half of 2024?
What recent clinical trials has BioStem Technologies (BSEM) initiated in 2024?
Has BioStem Technologies (BSEM) applied for Nasdaq uplisting in 2024?
